Methods for detection of circulating tumour cells (CTCs) and more readily, circulating tumour DNA (ctDNA) potentially allow for continual patient monitoring for emergence of ESR1 mutations and so, present opportunities for the early switchover of endocrine therapies once ESR1 mutations emerge [31, 32]. This evidence concerns the gene ESR1 and neoplasm.